Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Research Archives
Print | Email | Share | Comments (0)

Once-a-Month Dosing for Type 2s?


Aug 25, 2009

Scientists hope that a new GLP-1 analog will last longer in the body, allowing for less frequent dosing and fewer side effects.

A new glucagon-like peptide-1 (GLP-1) analog for type 2s that might require dosing only once a month is now in pre-clinical (animal) studies.  GLP-1, which increases insulin secretion from the pancreas, is a mighty helpful molecule, but with a sadly brief lifespan. It's broken down in the body within minutes by the enzyme DPP-4.  That's why drugs like Merck's Januvia, a DPP-4 inhibitor, is effective: blocking DPP-4 subsequently increases the amount of GLP-1 in the system.  

Another way to tackle the problem of GLP-1's vulnerability to DPP-4 is to make a GLP-1 analog: a molecule that works like GLP-1, but can hide from or resist DPP-4.  Byetta (exenatide), for example, is a GLP-1 analog that has been tweaked enough to stay in the system for awhile, but it still needs to be injected twice a day before meals.

The new GLP-1 analog (VRS-859), created by Versartis, is a recombinant fusion protein. That is, it's made up of exenatide attached to XTEN. XTEN is a water-loving amino acid sequence that "covers" exenatide, hiding it from DPP-4 and protecting it from breakdown. This will, it is hoped, let the GLP-1 carry out its good works for a longer time, allowing for less frequent dosing and fewer side effects.

Sources:

biospace.com/

versartis.com


Categories: Insulin, Medications Research, Research, Type 2 Issues



You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.